Ajanta Pharma Ltd., a specialty pharmaceutical formulation company, has released its Q2 FY25 results, showcasing a strong performance for the quarter and half-year ending on 30th September 2024.
Key Highlights:
Shareholders’ Payout
The Board of Directors approved the first interim dividend of ₹28 per share (face value of ₹2 per share), amounting to a total payout of ₹350 crore. With this, the cumulative payout for the financial year 2024-25 reaches ₹701 crore, accounting for 90% of the cash flow from operations in H1 FY25.
Q2 FY25 Performance (compared to Q2 FY24):
- Revenue from Operations: ₹1,187 crore, up 15% from ₹1,028 crore in Q2 FY24.
- EBITDA: ₹311 crore, a 7% increase from ₹291 crore, with an EBITDA margin at 26%.
- Profit After Tax (PAT): ₹216 crore, marking an 11% growth from ₹195 crore, with PAT margin at 18%.
H1 FY25 Performance (compared to H1 FY24):
- Revenue from Operations: Reached ₹2,332 crore, a 14% increase from ₹2,049 crore in H1 FY24.
- EBITDA: ₹642 crore, up 12% from ₹572 crore, with an EBITDA margin at 28%.
- Profit After Tax (PAT): ₹462 crore, up 15% from ₹403 crore, with PAT margin at 20%.
- Cash Flow from Operations (CFO): ₹776 crore, showcasing a strong EBITDA to CFO conversion of 121%.
- Free Cash Flow (FCF): Stood at ₹322 crore, with an FCF to PAT conversion of 70%.
- Return on Capital Employed (ROCE): Maintained a healthy level of 34%, with Return on Net Worth (RONW) at 26%.
Branded Generic Business
Ajanta Pharma’s branded generics segment continued to perform robustly, contributing significantly to the company’s revenue and profitability.
Ajanta Pharma’s results reflect its resilient business model, with consistent revenue growth and solid profit margins. The approved interim dividend underscores the company’s commitment to rewarding its shareholders, supported by healthy cash flow management and high returns on capital.
